What one share of Belite Bio holds
We are a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have significant unmet medical need such as (i) Geographic Atrophy (GA), the late atrophic (“dry”) form of age-related macular degeneration (AMD), and (ii) Stargardt disease type 1 (STGD1).
Belite Bio’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$2.31 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.10 |
| Cash and investments | $8.97 |
| Book value | $19.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$0.65 | — | — | — | −$0.80 |
| 2021 | — | −$1.01 | $0.01 | −$0.79 | — | −$1.47 |
| 2022 | — | −$0.63 | $0.02 | −$0.59 | — | $1.67 |
| 2023 | — | −$1.19 | $0.00 | −$1.12 | — | $3.10 |
| 2024 | — | −$1.18 | $0.00 | −$0.96 | — | $4.58 |
| 2025 | — | −$2.31 | $0.00 | −$1.10 | — | $19.59 |
Common questions about Belite Bio
How much does one share of Belite Bio earn?
Over its latest fiscal year, Belite Bio lost $2.31 for each share.
Does Belite Bio pay a dividend?
Belite Bio didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Belite Bio’s book value per share?
Belite Bio’s book value is $19.59 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of Belite Bio have?
Each share of Belite Bio has $8.97 of cash and investments, as of December 31, 2025.
What is Belite Bio’s free cash flow per share?
−$1.10 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has Belite Bio bought back shares?
Belite Bio’s share count rose about 282% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.